Curis (NASDAQ:CRIS) Posts Quarterly Earnings Results

Curis (NASDAQ:CRIS) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.14) by ($0.11), RTT News reports. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. The company had revenue of $2.38 million during the quarter, compared to the consensus estimate of $2.37 million. During the same period in the previous year, the business earned ($2.05) earnings per share.

Curis Trading Down 10.8 %

Shares of NASDAQ CRIS opened at $2.19 on Wednesday. The business has a 50-day moving average of $2.06 and a 200-day moving average of $3.13. The firm has a market capitalization of $18.55 million, a price-to-earnings ratio of -0.28 and a beta of 3.65. Curis has a 12 month low of $1.02 and a 12 month high of $16.93.

Analysts Set New Price Targets

CRIS has been the subject of a number of recent analyst reports. HC Wainwright reduced their target price on Curis from $20.00 to $16.00 and set a “buy” rating for the company in a report on Monday, March 31st. StockNews.com started coverage on shares of Curis in a research note on Wednesday, April 30th. They issued a “hold” rating on the stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.